Rhythm Pharmaceuticals, Inc.
IMCIVREE
acquired hypothalamic obesity
Resolved
7days ago
FDA decision · ~ Jun 30, 2026 estimated
What's at stake
The FDA's approval decision on IMCIVREE for acquired hypothalamic obesity is due ~ Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“Decision by Japan’s PMDA for IMCIVREE in acquired HO anticipated in the second half of 2026;”